NEW YORK, NY, September 12, 2013 --LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Ohr Pharmaceutical Inc. (NASDAQ: OHRP), a biotechnology company developing treatments for ophthalmic diseases. Ohr's lead product, squalamine eye drops, is being developed for patients with neovascular age-related macular degeneration (wet AMD) and has the potential to eliminate or reduce the need for intravitreal injections while still providing benefits to visual acuity. This development program is in a Phase II clinical trial with interim data expected in the second quarter of 2014.
"Patients with wet AMD are searching for options that reduce intravitreal injections, and squalamine eye drops may offer a safe and convenient delivery system for these patients," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "Ohr has the scientific expertise in place to enter the wet AMD market as a serious competitor, with potential to expand into other indications such as diabetic macular edema and retinal vein occlusion."
Ohr is developing squalamine as the first-ever topical treatment for wet AMD. The compound has a unique mechanism of action that leads to the inhibition of several growth factors (VEGF, PDGF, bFGF), while currently approved treatments target a single growth factor (VEGF). Preclinical data in Dutch belted rabbits demonstrate effective and continuous distribution of squalamine eye drops to the back of the eye at levels known to inhibit neovascularization associated with wet AMD. The ongoing Phase II trial is designed to position squalamine eye drops favorably in the wet AMD market, either for the elimination of or use in combination with injected treatments.
In a 46 page Initiation Report by LifeSci Advisors, we explain the scientific support for Ohr's clinical programs and the Company's focus on becoming a leader in ophthalmologic indications. The report discusses the potential competitive advantages of squalamine eye drops over existing treatments and how these advantages position the drug within the marketplace. We highlight the large revenue potential and dynamic nature of the wet AMD market, including the perception of intravitreal injections, and critically examine competing products and development programs.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing.LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
Ohr Pharmaceutical Inc. Contact:
Phone: (212) 682-8452
SOURCE: LifeSci Advisors